Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last €30.58 EUR
Change Today +0.485 / 1.61%
Volume 0.0
As of 3:39 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

atent applications relating to what is VectraDA testing. Business Strategy The company’s strategy is focused on executing three strategic imperatives, such as transition and expanding the hereditary cancer market; launching new products across a set of disease indications; and expanding its molecular diagnostic business internationally. Trademarks Myriad, BRACAnalysis, BRACAnalysis CDx, BART, COLARIS, COLARIS AP, MELARIS, myPath, myPlan, myChoice, Myriad myRisk, PANEXIA, PREZEON, Prolaris, myChoice HRD, Vectra, Vectraview, TruCulture, DiscoveryMAP and RodentMap are registered trademarks or trademarks of the company. Research and Development For the years ended June 30, 2015, the company had research and development expense of $75.5 million. Seasonality The company experiences seasonality in its testing business. The volume of testing is negatively impacted by the summer holiday season, which is generally reflected in the company’s fiscal first quarter (year ended June 2015). The company’s fiscal second quarter ending December 31 is generally strong as the company sees an increase in volume from patients who have met their annual insurance deductible. Conversely, fiscal third quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles. Patents and Proprietary Rights myRisk Hereditary Cancer: The company owns or has exclusive license rights to issued U.S. patents and pending U.S. patent applications relating to myRisk Hereditary Cancer testing. Subject to applicable extensions, the company anticipates that the expiration dates of these patents ranging from 2015 up to the last patent, if issued from the pending applications, expected to expire in 2035. BRACAnalysis: The company owns issued U.S. patents relating to BRACAnalysis testing, including BRACAnalysis CDx testing. These U.S. patents have terms that are expected to expire commencing in 2015, with the last patent expected to expire in 2025. BART: The company owns issued U.S. patents relating to BART testing. These U.S. patents have terms that are expected to expire commencing in 2015, with the last patent expected to expire in 2025. COLARIS and COLARIS AP: The company owns issued U.S. patents relating to COLARIS and COLARIS AP testing. These U.S. patents have terms that began to expire commencing in 2017, with the last patent expected to expire in 2026. Vectra DA: The company holds an exclusive license to pending U.S. patent applications relating to VectraDA testing. These U.S. applications, if issued as patents, would have terms that begin to expire commencing in 2030. Governmental Regulation The company’s laboratories are accredited by the College of American Pathologists (CAP), which is a Centers for Medicare & Medicaid Services-approved accreditation organization, they are typically subject to CAP inspections. The company is in material compliance with the Clinical Laboratory Improvement Amendments of 1988 and all applicable licensing laws and regulations. The company is subject to the Health Insurance Portability and Accountability Act of 1996 regulations and maintains an active compliance program that is designed to identify security incidents and other issues in a timely fashion and enable the company to remediate, mitigate harm or report if required by law. The company is subject to prosecution and/or administrative enforcement and increased civil and criminal penalties for non-compliance, including a new, four-tiered system of monetary penalties adopted under the Health Information Technology for Economic and Clinical Health Act. The company is also subject to enforcement by state attorneys general who were given authority to enforce the Health Insurance Portability and Accountability Act of 1996 under the Health Information Technology for Economic and Clinical Health Act. The company is also required to maintain information on and control over sales and distributors’ activities that might fall within the purview of the Foreign Corrupt Practices Act, its books and records provisions and its anti-bribery provisions. History Myriad Genetics, Inc. was founded in 199

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €30.58 EUR +0.485

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $18.56 USD +0.22
Alliance HealthCare Services Inc $6.78 USD +0.27
Genomic Health Inc $26.53 USD +0.72
QIAGEN NV €18.38 EUR +0.433
RadNet Inc $5.31 USD +0.27
View Industry Companies
 

Industry Analysis

MYD

Industry Average

Valuation MYD Industry Range
Price/Earnings 25.7x
Price/Sales 3.2x
Price/Book 3.2x
Price/Cash Flow 25.1x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.